Mostrar el registro sencillo

dc.contributor.authorRodríguez Grande, Jorge
dc.contributor.authorGozalo Margüello, Mónica
dc.contributor.authorGonzález Rico, Claudia
dc.contributor.authorFraile-Valcárcel, N.
dc.contributor.authorArnaiz de las Revillas Almajano, Francisco
dc.contributor.authorPalomino Cabrera, Rosalía
dc.contributor.authorFernández Sampedro, Marta 
dc.contributor.authorFariñas Álvarez, María del Carmen 
dc.contributor.authorGarcía Fernández, Cristina
dc.contributor.authorRodríguez Lozano, J.
dc.contributor.authorCalvo Montes, Jorge
dc.contributor.authorOcampo Sosa, Alain Antonio
dc.contributor.authorFariñas Álvarez, María Concepción
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2025-03-17T18:24:47Z
dc.date.available2025-03-17T18:24:47Z
dc.date.issued2024
dc.identifier.issn2950-5909
dc.identifier.urihttps://hdl.handle.net/10902/36031
dc.description.abstractThe development of novel culture-independent techniques of microbial identification has allowed a rapid progress in the knowledge of the nasopharyngeal microbiota and its role in health and disease. Thus, it has been demonstrated that the nasopharyngeal microbiota defends the host from invading pathogens that enter the body through the upper airways by participating in the modulation of innate and adaptive immune responses. The current COVID-19 pandemic has created an urgent need for fast-track research, especially to identify and characterize biomarkers to predict the disease severity and outcome. Since the nasopharyngeal microbiota diversity and composition could potentially be used as a prognosis biomarker for COVID-19 patients, which would pave the way for strategies aiming to reduce the disease severity by modifying such microbiota, dozens of research articles have already explored the possible associations between changes in the nasopharyngeal microbiota and the severity or outcome of COVID-19 patients. Unfortunately, results are controversial, as many studies with apparently similar experimental designs have reported contradictory data. Herein we put together, compare, and discuss all the relevant results on this issue reported to date. Even more interesting, we discuss in detail which are the limitations of these studies, that probably are the main sources of the high variability observed. Therefore, this work is useful not only for people interested in current knowledge about the relationship between the nasopharyngeal microbiota and COVID-19, but also for researchers who want to go further in this field while avoiding the limitations and variability of previous works.es_ES
dc.format.extent2 p.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rights© 2024 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This work is licensed under a Creative Commons Attribution 4.0 International License.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceCMI communications, 2024, 1(Supplement 1), 625-626es_ES
dc.titleThe nasopharyngeal microbiome in COVID-19 infectiones_ES
dc.typeinfo:eu-repo/semantics/conferenceObjectes_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.cmicom.2024.100013es_ES
dc.rights.accessRightsopenAccesses_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2024 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This work is licensed under a Creative Commons Attribution 4.0 International License.Excepto si se señala otra cosa, la licencia del ítem se describe como © 2024 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This work is licensed under a Creative Commons Attribution 4.0 International License.